Retinoid Mixture for 5-HT2B Receptor Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions related to 5-HT2B serotonin receptor overactivity, such as migraine, anxiety, irritable bowel syndrome, ocular hypotension, heart valve disease, and MDMA abuse, often come with negative side effects and are not recommended for long-term therapy.
Innovation Solution
A retinoid mixture comprising cis and trans retinyl esters, particularly retinyl acetate, with a cis/trans ratio of less than 0.03, is used to bind to and antagonize the 5-HT2B serotonin receptor, providing an alternative therapy for these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional 5-HT2B receptor antagonists are used to treat migraine and other conditions, then the symptoms can be treated, but negative side effects occur and long-term therapy is not recommended
Solution Approach 1:
The patent changes the chemical structure parameters of the 5-HT2B receptor antagonist by using retinoid compounds with specific cis/trans isomer ratios (less than 0.03 cis/trans ratio) instead of conventional antagonists. This parameter change in molecular structure leads to improved treatment effectiveness while reducing negative side effects, enabling long-term therapy safety.
2Reliability
If triptan-class pharmaceuticals are used for migraine treatment, then migraine symptoms can be managed, but they are not recommended for people with cardiovascular disease
Solution Approach 1:
The patent introduces retinoid compounds as an intermediary substance that acts as a 5-HT2B receptor antagonist. This intermediary provides migraine treatment efficacy without the cardiovascular risks associated with triptan-class pharmaceuticals, making it a safer alternative for patients with cardiovascular disease.
3Duration of action of moving object
If existing 5-HT2B receptor antagonists are used for long-term therapy, then conditions can be managed, but negative side effects make them unsuitable for prolonged use
Solution Approach 1:
The patent modifies the pharmacological parameters of 5-HT2B receptor antagonists by employing retinoid compounds with specific molecular characteristics (cis/trans ratio less than 0.03). This parameter modification enables long-term therapy without the negative side effects that limit the duration of use for conventional antagonists.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The retinoid mixture effectively antagonizes the 5-HT2B receptor, reducing the symptoms associated with these conditions without the negative side effects of existing treatments, thus offering a safer and more effective long-term solution.
Implementation Method 1
A retinoid mixture comprising cis and trans retinyl esters, particularly retinyl acetate, with a cis/trans ratio of less than 0.03, is used to bind to and antagonize the 5-HT2B serotonin receptor
Data Source
AI summary
The present invention relates to novel compositions comprising a retinoid mixture of cis and trans isomers of a retinyl ester, particularly retinyl acetate, with a cis/trans ratio of less than 0.03 as well as the use thereof for the treatment, prevention and lessening of the symptoms of diseases and conditions which can be treated with 5-HT2B serotonin receptor antagonists, including but not limited to diseases or conditions selected from migraine headaches, anxiety, ocular hypotension, heart valve disease, irritable bowel syndrome, and MDMA (commonly called “ecstasy”) abuse.